Climb Bio's CLYM116 Shows Durable APRIL Suppression in Phase 1 Trial
Climb Bio reported Phase 1 data for anti-APRIL antibody CLYM116 demonstrating a ~29-day half-life and >90% APRIL suppression, supporting every-12-week dosing. The company expects initial NAVIGATE-2 data in H1 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day